Objective: To investigate the association between the CYP3A5 genetic polymorphism and
the serum concentrations of carbamazepine (CBZ), to provide guidance for individualized …

Two research groups have reported the effect of genetic polymorphisms of CYP2C9 and
CYP2C19 on the pharmacokinetic parameters of phenytoin in Japanese epileptic patients …

Abstract Cytochrome P450 (CYP) 2C9 hydroxylates about 16% of drugs in current clinical
use. Of special interest are those with a narrow therapeutic index, such as S‐warfarin …

Objective: To search for ethnic variability in the impact of cytochrome P 450 2C9 (CYP2C9)
polymorphism. Methods: CYP2C9 allelic variants related to impaired CYP2C9 metabolism …

CYP2C9 and CYP2C19 are important drug metabolizing enzymes and together metabolize
about 18% of currently available drugs. Some of the important groups of drugs that are …

Aims CYP2C9 is a major enzyme in human drug metabolism and the polymorphism
observed in the corresponding gene may affect the therapeutic outcome during treatment …

Objective To explore the influence of CYP2C9, CYP2A6, ACSM2A, CPT1A gene
polymorphisms on valproic acid (VPA) and its role in metabolism-related liver dysfunction in …

Phenytoin (PHT) is primarily metabolized to 5-(4′-hydroxyphenyl)-5-phenylhydantoin (p-
HPPH), accounting for 67–88% of an administered dose in humans. p-HPPH is formed by …

Abstract Objective: Among Caucasians, a lack of cytochrome P 450 enzyme CYP2D6 is
observed in 5–10% of individuals, named poor metabolizers (PMs). A consequence may be …

CYP2C9 is a major liver enzyme responsible of the metabolism of many clinically important
drugs. The presence of CYP2C9 genetic polymorphisms has been associated with marked …